Most U.S. neuromuscular therapy policies had restrictions beyond FDA labels
Original source
U.S. health plan coverage of Neuromuscular Disease Therapies: An assessment of policy availability and restrictions. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
A study of U.S. Medicaid programs and major commercial insurers found that 96% of covered neuromuscular disease therapies had restrictions beyond their FDA-approved indications. The review included therapies for amyotrophic lateral sclerosis (ALS) and four other neuromuscular diseases. Many policies required reauthorization, and average approval periods were six months initially and 10 months for renewals.
Why this matters
These policies may affect people with ALS and other neuromuscular diseases who need treatment through U.S. insurance. Requirements such as step therapy, limited prescriber criteria and short approval periods may delay access or interrupt ongoing care, although this study assessed policies rather than patient outcomes.
Limitations and context
The study analyzed publicly available coverage policies, not whether individual patients experienced delays or treatment interruptions. Of 1,204 potential policy decisions, 908 had publicly available policies, and only 558 included reauthorization criteria. Requirements varied by insurer, disease and therapy, so the findings do not apply equally to every plan.